Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings per share (EPS) of ($0.03) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.07) and the highest is $0.01. Vanda Pharmaceuticals posted earnings of $0.14 per share in the same quarter last year, which indicates a negative year over year growth rate of 121.4%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year earnings of $0.06 per share for the current fiscal year, with EPS estimates ranging from ($0.14) to $0.25. For the next year, analysts expect that the business will post earnings of $0.93 per share, with EPS estimates ranging from $0.16 to $1.69. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.08). The firm had revenue of $47.71 million for the quarter, compared to analyst estimates of $51.74 million. Vanda Pharmaceuticals had a net margin of 10.92% and a return on equity of 8.07%. Vanda Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.14 earnings per share.
A number of equities research analysts recently weighed in on VNDA shares. BidaskClub lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. ValuEngine lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Cantor Fitzgerald lowered shares of Vanda Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $38.00 to $30.00 in a report on Wednesday, February 6th. Stifel Nicolaus reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, February 6th. Finally, TheStreet lowered shares of Vanda Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, February 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $33.63.
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $19.41, for a total transaction of $740,802.06. Following the completion of the transaction, the chief executive officer now directly owns 1,217,136 shares of the company’s stock, valued at approximately $23,624,609.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Patrick Kelly sold 8,751 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $19.88, for a total transaction of $173,969.88. Following the transaction, the chief financial officer now directly owns 218,497 shares of the company’s stock, valued at $4,343,720.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,274 shares of company stock valued at $1,164,127. 8.20% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of VNDA. Advisor Group Inc. lifted its position in shares of Vanda Pharmaceuticals by 27.3% in the 1st quarter. Advisor Group Inc. now owns 3,712 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 796 shares during the last quarter. LS Investment Advisors LLC lifted its position in shares of Vanda Pharmaceuticals by 109.3% in the 4th quarter. LS Investment Advisors LLC now owns 3,662 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,912 shares during the last quarter. Pearl River Capital LLC lifted its position in shares of Vanda Pharmaceuticals by 6,148.0% in the 1st quarter. Pearl River Capital LLC now owns 6,248 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 6,148 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth about $117,000. Finally, Adams Diversified Equity Fund Inc. bought a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth about $120,000. Institutional investors own 98.58% of the company’s stock.
VNDA traded up $0.39 during trading hours on Friday, reaching $16.38. 18,850 shares of the stock traded hands, compared to its average volume of 840,368. The firm has a market cap of $846.89 million, a price-to-earnings ratio of 33.92 and a beta of 0.44. Vanda Pharmaceuticals has a fifty-two week low of $13.66 and a fifty-two week high of $33.44.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.